Both RUNX1 mRNA and protein levels were observed to be significantly reduced in p53 KO MDS cells after lenalidomide treatment, suggesting that the downregulation of RUNX1 is induced by p53 deficiency [99]. This evidence concerns the gene TP53 and myelodysplastic syndrome.